Evidence map›Paper›PMID 27885422›Full record

ArticleVirchows Archiv : an international journal of pathology2017

CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma.

Elena Sanmartín, Fernando Ortiz-Martínez, Eloy Pomares-Navarro, Araceli García-Martínez, Montserrat Rodrigo-Baños, Marta García-Escolano, Leire Andrés, Enrique Lerma, Francisco I Aranda, Pascual Martínez-Peinado and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Investigating the Role ofInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Elena SanmartínResearch Unit, University General Hospital of Alicante, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain. sanmartin_ele@gva.es.
Fernando Ortiz-MartínezResearch Unit, University General Hospital of Alicante, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain.
Eloy Pomares-NavarroResearch Unit, University General Hospital of Alicante, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain.
Araceli García-MartínezResearch Unit, University General Hospital of Alicante, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain.
Montserrat Rodrigo-BañosResearch Unit, University General Hospital of Alicante, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain.
Marta García-EscolanoResearch Unit, University General Hospital of Alicante, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain.
Leire AndrésPathology Department, Hospital de Cruces, Plaza de Cruces n° 2, ZC: 48903, Barakaldo, Spain.
Enrique LermaPathology Department, Hospital de la Santa Creu i Sant Pau, C/ Sant Quintí 87-89, ZC: 08041, Barcelona, Spain.
Francisco I ArandaPathology Department, University General Hospital of Alicante, C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain.
Pascual Martínez-PeinadoBiotechnology Department, Immunology Division, University of Alicante, ZC: 03080, Alicante, Spain.
José M Sempere-OrtellsBiotechnology Department, Immunology Division, University of Alicante, ZC: 03080, Alicante, Spain.
Gloria PeiróResearch Unit, University General Hospital of Alicante, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), and Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), C/ Pintor Baeza 12, ZC: 03010, Alicante, Spain.
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESInstituto de investigación sanitaria y biomédica de AlicanteUniversity of Alicante · ESHospital de Cruces · ESHospital de Sant Pau · ESHospital General Universitario de Alicante Doctor Balmis · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the relationship between CD44 and Forkhead box P3 (FOXP3) gene expression in cell lines and breast carcinomas and their association with clinicopathological variables and patient outcome. We assessed messenger RNA (mRNA) expression of CD44 and FOXP3 by quantitative real-time PCR and determined the number of FOXP3+ Tregs by immunohistochemistry in 264 breast cancer specimens. CD44 was stimulated with hyaluronan treatment, and the accompanying changes in FOXP3 mRNA expression in breast cancer cell lines representing breast cancer subtype were assessed. We found that lower CD44 expression correlated with the presence of necrosis, lymph-vascular invasion, grade 3 tumors, and aggressive phenotype (HER2 and basal-like). FOXP3 mRNA correlated positively with CD44 mRNA expression and Treg content. Moreover, stimulation of CD44 expression by hyaluronan in cell lines increased FOXP3 expression, which supports that their regulation is associated. Survival analysis revealed that low CD44 expression is associated with higher frequency of recurrence. Our findings indicate that CD44 has a regulatory role in FOXP3 expression and is associated with good prognostic factors in breast cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsDisease-Free SurvivalFemaleForkhead Transcription FactorsHumansHyaluronan ReceptorsImmunohistochemistryMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisT-Lymphocytes, RegulatoryBiomarkers, TumorCD44 protein, humanForkhead Transcription FactorsFOXP3 protein, humanHyaluronan ReceptorsBreast carcinomaCD44FOXP3mRNA expressionPrognosis

Identifiers

PMID27885422
OpenAlexW2554891127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.